Nausea sits at the top of the list, usually mild, usually concentrated in the first few weeks after a dose increase, and usually fading as the body adjusts
It should be kept in mind that one of the reasons for the difference between the results of this study and our research in terms of HbA1c is that our study was conducted on all people with and without diabetes, while this study was conducted on participants with at least 8 years of history of diabetes and, therefore
Mounjari works by 2 mechanisms because it is not only a GLP-1 receptor agonist, but it is also GIP receptor agonist (Glucose Dependent Insulinotropic polypeptide)
Who Are Hers and Hims GLP-1 Clinics Not For
Tastuzawa Y, Sekinaka K, Suda T, Matsumoto H, Otabe H, Nonoyama S, et al